治疗用重组抗体、蛋白质的全球市场:规模,占有率,趋势,预测(2022年~2028年)
市场调查报告书
商品编码
1084478

治疗用重组抗体、蛋白质的全球市场:规模,占有率,趋势,预测(2022年~2028年)

Recombinant Therapeutic Antibodies and Proteins Market - Size, Share, trends, and Forecast, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球治疗用重组抗体、蛋白质的市场规模,由于抗体为基础的治疗药的开发,哺乳类表现系统、微生物表现系统的发展等所促进。

本报告提供全球治疗用重组抗体、蛋白质市场调查,市场概要,市场规模和预测,趋势,成长要素,阻碍因素,各医药品分类、用途、地区的分析,及竞争情形等资讯。

目录

第1章 调查目的、前提条件

  • 调查目的
  • 假设
  • 简称

第2章 市场展望

  • 报告的说明
    • 市场定义和范围
  • 摘要整理
    • 市场明细:各医药品分类
    • 市场明细:各用途
    • 市场明细:各地区
  • Coherent Opportunity Map(COM)

第3章 市场动态,法规,及趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 市场趋势
  • 开发平台分析
  • 医药品开发的课题
  • 新市场进入者
  • 法规情境
  • PEST分析
  • 波特分析

第4章 全球治疗用重组抗体、蛋白质市场:各医药品分类(2017年~2028年)

  • 简介
  • 血浆蛋白质
  • 成长因素
  • 融合蛋白质
  • 单株抗体
  • 荷尔蒙
  • 酵素
  • 凝血因子
  • 其他

第5章 全球治疗用重组抗体、蛋白质市场:各用途(2017年~2028年)

  • 简介
  • 肿瘤学
  • 血液学
  • 免疫学
  • 内分泌学
  • 感染疾病
  • 循环系统疾病
  • 其他

第6章 全球治疗用重组抗体、蛋白质市场:各地区(2017年~2028年)

  • 简介
  • 北美
  • 南美
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第7章 竞争情形

  • 热图分析
  • 企业简介
    • Abbott*
    • Amgen Inc.
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • Johnson and Johnson
    • Merck &Co.
    • Novo Nordisk
    • Pfizer Inc.
    • Sanofi SA
  • 分析师的见解

第8章 Section

简介目录
Product Code: CMI1981

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.

Market Dynamics

Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.

Key features of the study:

This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans

Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:

North America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

U.S.

Canada

Latin America Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

GCC

Israel

Rest of Middle East

Africa Recombinant Therapeutic Antibodies and Proteins Market

By Drug Class:

Plasma Protein

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

By Application:

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Diseases

Others

By Country:

North Africa

South Africa

Central Africa

Company Profiles

Abbott Laboratories*

Company Overview

Product Portfolio

Key Highlights

Financial Overview

Market Strategy

Amgen Inc.

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche

Johnson and Johnson

Merck & Co.

Novo Nordisk

Pfizer, Inc.

Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Pipeline Analysis
  • Drug Development Challenges
  • New Market Entrants
  • Regulatory Scenario
  • PEST Analysis
  • Porter's Analysis

4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Plasma Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Growth Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Fusion Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hormones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Coagulation Factors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Endocrinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Infectious Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Cardiovascular Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Abbott*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • F. Hoffmann-La Roche
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Johnson and Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Novo Nordisk
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Market Strategy
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact